Investigating the cancer-causing potential of specific KRAS gene mutations in pancreatic cancer
Official title: Defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants
Funded at Weill Medical Coll of Cornell Univ · NIH-11058669 · Data updated 2026-11-12
This study is looking at how certain changes in the KRAS gene can lead to pancreatic cancer, with the hope of finding new ways to treat this tough disease by using special mouse models that act like human cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 25, 2024 |
| Project end | October 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $636,046 |
| NIH project number | 1R01CA290616-01A1 |
| Project ID | NIH-11058669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, especially those with KRAS mutations.
✕Less likely to help
Patients with pancreatic cancer who do not have KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer often diagnosed at advanced stages. It aims to understand how different mutations in the KRAS gene contribute to the development of PDAC and identify potential therapeutic targets. By using advanced mouse models that mimic human cancer mutations, the study will explore how these mutations affect pancreatic cell behavior and cancer progression. The goal is to uncover specific vulnerabilities associated with less common KRAS mutations that could lead to new treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with pancreatic cancer, particularly those with specific KRAS mutations.
How similar studies have gone: Other research has shown promise in targeting KRAS mutations in cancer, but the specific focus on KRASG12R mutations in PDAC is relatively novel.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Chandwani, Rohit — Weill Medical Coll of Cornell Univ
- Study coordinator: Chandwani, Rohit
Related research
Other NIH-funded projects on the same topics.
-
Targeting epigenomic regulators to assault pancreatic cancer replication stress
This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.
-
Neoantigen vaccines in pancreatic cancer: overcoming resistance to improve immune responses
This grant supports testing advanced neoantigen vaccines in pancreatic cancer to boost patients' immune responses and potentially improve outcomes.
-
CD11b-activating drug to make pancreatic cancer respond to immunotherapy
A study to see if a CD11b-activating drug (GB1275) can help pancreatic cancer patients respond better to immunotherapy when combined with standard chemotherapy and PD-1 blockers.
-
Targeting autophagy to treat KRAS-mutant pancreatic cancer
This grant explores using approved drugs to block autophagy in KRAS-mutant pancreatic cancer to improve treatment outcomes.
-
Reprogramming PDAC stroma by targeting blood clotting in the tumor environment
A cancer research grant aimed at turning the tough, fibrous pancreatic cancer environment into one that helps treatments work better and supports the body’s immune response.
-
Understanding paracrine signals in pancreatic cancer to improve drug delivery
A patient-focused look at how the tumor’s signaling networks affect treatment delivery in pancreatic cancer and how targeting these networks could help therapies reach tumors more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.